Months without UVB sunlight during polar night collapse cutaneous vitamin D synthesis — tracking the physiological cascade from skin to bone
Before deployment to a polar research station, personnel typically carry sufficient vitamin D stores built up through summer sun exposure. Understanding the cutaneous synthesis pathway — and how efficiently the skin manufactures vitamin D from UVB photons — establishes the baseline against which months of polar darkness will be measured.
Vitamin D synthesis begins when a UVB photon (290–315 nm) penetrates the epidermis and is absorbed by 7-dehydrocholesterol (7-DHC), a cholesterol precursor embedded in the plasma membrane of keratinocytes in the basal and spinous layers. Photon absorption breaks open the B-ring of the sterol, producing previtamin D3 — a chemically unstable intermediate.
Over the following hours, previtamin D3 undergoes a temperature-dependent, non-enzymatic isomerization in the plasma membrane, rearranging into cholecalciferol (vitamin D3). Unlike previtamin D3, cholecalciferol is thermodynamically favored to leave the membrane, diffusing into the dermal capillary bed where it binds vitamin D-binding protein (DBP) for transport into systemic circulation.
This is the only step in the entire vitamin D pathway that requires sunlight — every downstream step (hepatic and renal hydroxylation) proceeds identically whether the D3 originated from skin or from a swallowed capsule.
A single whole-body exposure to one minimal erythemal dose (MED) of summer sun generates the equivalent of roughly 10,000–25,000 IU of vitamin D3 — far more than any standard oral supplement dose, yet the skin self-limits: excess previtamin D3 is photodegraded into inert lumisterol and tachysterol, making sunlight-derived vitamin D toxicity essentially impossible.
Effective UVB synthesis depends on the solar zenith angle — how directly overhead the sun sits. At low zenith angles (sun near the horizon), the UVB path length through stratospheric ozone lengthens dramatically, absorbing nearly all synthesis-capable photons before they reach the ground. Above roughly 35° latitude, this creates a well-documented "vitamin D winter": little or no cutaneous synthesis for weeks to months even without literal polar night.
At polar research stations sitting at 75–90° latitude (e.g., Concordia, Vostok, the South Pole, McMurdo in deep winter), this effect is total: the sun does not merely sit low, it disappears below the horizon entirely for roughly four to six months, depending on exact latitude.
Cloud cover, atmospheric ozone thickness, and even snow albedo (which can reflect UVB back onto exposed skin) modulate synthesis during the sunlit months, but none of these factors matter once the sun is geometrically absent.
Polar medicine programs — the US Antarctic Program, British Antarctic Survey, and the French-Italian Concordia Station among them — increasingly screen incoming winter-over personnel with a baseline serum 25(OH)D measurement before the station is sealed off for the dark season. Crew members arriving with borderline or insufficient levels (21–29 ng/mL) are disproportionately likely to become frankly deficient by mid-winter.
Some protocols recommend a pre-departure "loading" strategy — elevated supplementation in the weeks before deployment — specifically to build a larger circulating and tissue reservoir that buffers the coming months without any UVB input at all.
The moment the sun drops below the horizon, the cutaneous vitamin D synthesis pathway does not gradually taper — it stops. What follows is governed entirely by pharmacokinetics: the circulating half-life of 25-hydroxyvitamin D determines how quickly the body's reserve, built over months of summer sun, begins to drain away.
Effective vitamin D synthesis actually ceases before the sun technically disappears. As the solar zenith angle climbs past roughly 80°, the UVB path length through the atmosphere grows so long that stratospheric ozone absorbs essentially all synthesis-capable wavelengths, even though visible light — and a technical "sunrise" — persists for a few more days or weeks.
For practical purposes, station medical staff treat the onset of polar night as the abrupt end of any cutaneous contribution to vitamin D status, regardless of the exact astronomical date the sun crosses the horizon.
Serum 25(OH)D is the standard clinical biomarker of vitamin D status because of its relatively long half-life (~2–3 weeks) compared to the active hormone calcitriol (1,25-dihydroxyvitamin D, half-life measured in hours). Once cutaneous input reaches zero, serum 25(OH)D follows approximately first-order decay:
D(t) = D_floor + (D₀ − D_floor) × 0.5^(t / t½)
Starting from a summer baseline of ~34 ng/mL with a 3-week half-life, a station physician can expect serum levels to fall to roughly 24 ng/mL by week 2, 17 ng/mL by week 4, and approach single digits by week 10–12 if no countermeasure is introduced — crossing the deficiency threshold (20 ng/mL) within the first month of darkness.
Because the decay is exponential rather than linear, the fastest absolute drop in serum 25(OH)D happens in the first few weeks of polar night — precisely when crews are least likely to perceive any symptoms, since clinically apparent effects of deficiency typically lag weeks to months behind the biochemical decline.
Multiple Antarctic and Arctic overwintering studies — from British Antarctic Survey physiological monitoring to French-Italian Concordia Station cohorts — have repeatedly documented the same pattern: serum 25(OH)D measured at station closure in autumn is significantly higher than levels measured at the depth of winter, with unsupplemented personnel commonly showing 40–60% relative declines by the winter nadir, generally reached in the final weeks before sunrise.
As serum 25(OH)D continues its exponential decline through the darkest weeks of the polar night, it crosses clinically defined thresholds that trigger a cascading compensatory response. The kidney's ability to produce active calcitriol falls, intestinal calcium absorption drops, and the parathyroid glands begin working overtime to defend serum calcium — at the skeleton's expense.
25-hydroxyvitamin D is not biologically active on its own — it must be converted in the kidney by 1-alpha-hydroxylase into calcitriol (1,25-dihydroxyvitamin D), the hormone that actually drives intestinal calcium absorption. As substrate (25(OH)D) becomes scarce, calcitriol production falls, and active intestinal calcium absorption efficiency drops from a well-supplemented 30–40% to as low as 10–15%.
The parathyroid glands monitor ionized serum calcium continuously via the calcium-sensing receptor (CaSR) on their surface. As dietary calcium absorption falls short of the body's needs, ionized calcium begins to drift downward, and the parathyroid glands respond by secreting more parathyroid hormone (PTH).
Elevated PTH acts through three coordinated mechanisms to defend serum calcium: it increases renal tubular calcium reabsorption (conserving calcium that would otherwise be excreted), it stimulates whatever residual renal 1-alpha-hydroxylase activity remains (a partial, self-limiting compensation), and — most consequentially over weeks to months — it activates osteoblasts to express RANKL, which drives osteoclast differentiation and bone resorption.
This third mechanism liberates calcium and phosphate directly from the skeletal matrix into the bloodstream. It is an effective short-term fix for serum calcium, but it is achieved by continuously demineralizing bone — precisely the mechanism that, sustained over an entire polar winter, drives measurable bone turnover marker elevation.
Secondary hyperparathyroidism can drive PTH from a normal baseline of roughly 35 pg/mL to 80–130 pg/mL by the depth of winter in deficient individuals — a two- to fourfold elevation entirely attributable to the loss of UVB-driven vitamin D synthesis.
Published surveillance from Antarctic overwintering programs consistently finds 60–90% of unsupplemented personnel crossing into biochemical deficiency (<20 ng/mL) by the August–September winter nadir, with mean serum 25(OH)D commonly bottoming out in the 8–15 ng/mL range — well into the range associated with measurable secondary hyperparathyroidism.
Weeks of secondary hyperparathyroidism and vitamin D deficiency do not stay confined to a lab value. The downstream effects reach the skeleton, skeletal muscle, the innate immune system, and — compounded by the psychological weight of continuous darkness — mood and cognition, together constituting what polar medicine literature has long called "winter-over syndrome."
Chronic secondary hyperparathyroidism means continuous osteoclastic resorption without adequate compensatory bone formation. Biochemical bone turnover markers — C-terminal telopeptide (CTX, a resorption marker) and procollagen type I N-propeptide (P1NP, a formation marker) — both rise, but resorption typically outpaces formation, producing a net negative bone balance over the winter months.
In severe, prolonged deficiency, the defect shifts from simple bone loss to a mineralization defect: newly laid-down osteoid fails to calcify properly, the hallmark of osteomalacia. Polar personnel are doubly disadvantaged here, since confined station life during the dark months also tends to reduce weight-bearing physical activity, removing a second protective input to bone density.
Vitamin D receptors (VDR) are expressed directly in skeletal muscle tissue, particularly influencing Type II (fast-twitch) fiber function. Deficiency is associated with proximal muscle weakness, slower reaction times, and increased fall risk — a meaningful concern on an icy, physically demanding station.
Calcitriol also induces expression of cathelicidin and defensin antimicrobial peptides in monocytes and macrophages, a core component of innate immune defense against respiratory pathogens. Reduced vitamin D status has been associated with increased incidence of upper respiratory infection in several confined-population and polar cohort studies — a particular concern in stations where a single introduced pathogen can circulate through the entire crew.
Polar night compounds two distinct biological stressors simultaneously. Seasonal affective disorder (SAD) arises largely from the loss of retinal light input disrupting circadian melatonin and serotonin regulation — a photoperiod effect independent of vitamin D. But vitamin D receptors are also expressed in brain regions that regulate serotonin synthesis via the tryptophan hydroxylase 2 (TPH2) gene, giving vitamin D deficiency its own plausible, additive contribution to mood disturbance.
Polar psychology literature documents "winter-over syndrome" — irritability, insomnia, cognitive slowing, and interpersonal friction — in a substantial fraction of overwintering crews, with subsyndromal depressive symptoms reported in roughly 30–50% of personnel at some point during the dark season.
Antarctic winter-over research has repeatedly found that the depth of the darkness correlates with both mood disturbance severity and biochemical vitamin D deficiency — two curves that rise and fall together across the same months, making the two conditions extremely difficult to fully disentangle in the field.
Because every step of vitamin D metabolism downstream of the skin is identical whether the source is cutaneous or oral, supplementation can fully substitute for absent sunlight. Modern polar stations combine oral cholecalciferol dosing, UV-B phototherapy, and monitoring protocols to keep personnel out of the deficient range for the entire dark season.
Standard maintenance intake (600–800 IU/day) is calibrated for a population with substantial background sun exposure — it is inadequate to counter total UVB absence for months at a time. Polar station protocols typically prescribe 1,000–4,000 IU/day of cholecalciferol (vitamin D3, not ergocalciferol/D2) for the duration of the dark season, as D3 raises and sustains serum 25(OH)D more effectively than D2 at equivalent doses.
As a rough clinical rule of thumb, each additional 100 IU/day of D3 raises steady-state serum 25(OH)D by roughly 0.7–1 ng/mL, reaching a new equilibrium over approximately 8–12 weeks. For personnel who begin winter already deficient, a front-loaded bolus regimen — commonly 50,000 IU once weekly for eight weeks — is used clinically to correct the deficit faster than daily dosing alone, then transitioned to a daily maintenance dose.
Some stations supplement or replace oral dosing with narrowband UV-B lamps (peak output near 297 nm, matching the natural cutaneous action spectrum) delivered in dedicated "sun rooms" or light-therapy booths. Because the mechanism is identical to natural sunlight — 7-DHC photolysis in the skin — this approach restores the complete natural pathway rather than only its endpoint.
Sub-erythemal dosing protocols are essential: exposure is calibrated well below the dose that would cause skin reddening, since UV-B still carries the same DNA-damage and photoaging risks as natural sunlight regardless of source, and the self-limiting photodegradation that prevents toxicity from natural sun applies equally to lamp exposure.
Effective countermeasure programs pair dosing with periodic serum 25(OH)D and PTH monitoring — often via dried blood spot sampling that can be processed with minimal equipment and, where telemedicine bandwidth allows, interpreted remotely. The US Antarctic Program and similar polar medicine bodies have incorporated seasonal vitamin D supplementation directly into standard station medical protocols for winter-over personnel, reflecting decades of accumulated deficiency data from earlier, unsupplemented crews.
With consistent 2,000–4,000 IU/day dosing started at the onset of polar night, station medical data show serum 25(OH)D can be maintained comfortably in the sufficient range (>30 ng/mL) through the entire dark season — essentially eliminating the deficiency curve that unsupplemented crews experience.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Oral Vitamin D3 | Bypasses skin; liver 25-hydroxylation, renal 1α-hydroxylation unchanged | Daily (1,000–4,000 IU) or weekly bolus (50,000 IU) cholecalciferol dosing | Cheap, simple, no equipment; slower onset (~8–12 wks to steady state) |
| UV-B Phototherapy Lamp | Recreates natural cutaneous synthesis (7-DHC → previtamin D3 → D3) | Narrowband 297 nm lamp exposure, sub-erythemal dosimetry required | Physiologically complete pathway; needs dedicated equipment & dosing protocol |
| Sunlight Simulation Lamp | Broad-spectrum bright light incl. some UV; also addresses circadian/SAD symptoms | High-lux full-spectrum lamps used for mood/circadian therapy, variable UVB output | Dual benefit for SAD symptoms; inconsistent vitamin D contribution alone |
| Combined Protocol | Oral D3 baseline plus UV-B lamp and bright-light circadian therapy | Layered maintenance dosing with periodic serum 25(OH)D / PTH monitoring | Most robust; standard approach at well-resourced modern polar stations |